• Cellectar Biosciences Inc CLRB.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -83 cents. The mean expectation of four analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -43 cents to -26 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Cellectar Biosciences Inc's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $14.66 million.

• Cellectar Biosciences Inc shares had fallen by 13.1% this quarter and lost 32.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Cellectar Biosciences Inc is $13.50

This summary was machine generated from LSEG data November 18 at 10:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)